Investigation of Differences in P53 Gene Polymorphisms between Schizophrenia and Lung Cancer Patients in the Turkish Population by Özbey, Ulku et al.
SAGE-HindawiAccess to Research
GeneticsResearch International
Volume 2011, Article ID 483851, 9 pages
doi:10.4061/2011/483851
Research Article
InvestigationofDifferences inP53 Gene
Polymorphisms between Schizophreniaand LungCancer
PatientsintheTurkish Population
Ulku ¨ Ozbey,1 H¨ useyin Y¨ uce,2 MustafaNamli,2 andTamer Elkiran3
1GeneticDepartment, Faculty of Veterinary Medicine,Y¨ uz¨ unci Yil University, Zeve Campus, 65080 Van, Turkey
2Department of Medical Biology and Genetics, Faculty of Medicine, Firat University, 23119 Elazig, Turkey
3Psychiatry Hospital, 23200 Elazig, Turkey
Correspondence should be addressed to Ulku ¨ Ozbey, uozbey76@hotmail.com
Received 30 September 2010; Revised 22 December 2010; Accepted 31 December 2010
Academic Editor: Haim Werner
Copyright © 2011 Ulku ¨ Ozbey et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. The reduced incidence ofcancer observed in schizophrenia patients maybe related to diﬀerences in genetic background.
It has been suggested that genetic predisposition towards schizophrenia is associated with reduced vulnerability to lung cancer,
and p53 gene is one of the candidate genes. In our study, we aimed to investigate polymorphisms in the BstUI in exon 4 and
MspI in intron 6 restriction sites of the p53 gene in Turkish schizophrenia patients, lung cancer patients, and controls. Material
and Methods. Allele and genotype incidence of these polymorphisms with their haplotype combinations were studied in 100
Turkish lung cancer and schizophrenia patients and 100 controls without malignant and schizophrenia diseases. The genotype
characteristics were determined by PCR-based RFLP method using DNA extracted from peripheral blood. Results.F o rt h eB s t U I
and MspI polymorphism, there were found signiﬁcant diﬀerences in the genotype and allele frequencies between schizophrenia
and lung cancer patients with control groups (P<. 01). The analysis based on haplotype frequencies showed the presence of
BstUI-MspI 2-1 haplotype in cancer patients (12%) in contrast to the absence of this haplotype in schizophrenia and controls.
Only in lung cancer patients we found both signiﬁcant decrease of A1 allele of the p53 codon 72 (OR0.23, 95% CI0.9–0.58) and
A1/A1 homozygous genotype (P<. 0001, OR0.19). Conclusion. The results of this study suggest a protective eﬀect of A1 allele
againstlung cancer, and the p53 MspI polymorphism maymodify the susceptibility to lung cancer as a single factor rather thanin
combination with BstUI polymorphism.
1.Introduction
The relationship between schizophrenia and cancer has
posed an epidemiological puzzle for decades [1]. Lower
incidenceof malignancies, especially lung cancer, in patients
of schizophrenia compared to the general population has
been reported in several studies [2, 3]. Recently, reduced
risk of cancer in patients of schizophrenia has been
reported in an additional study. Theories proposed to
date attempting to explain the reduced risk of cancer in
schizophrenia patients focused on environmental, genetic,
pharmacological, and psychosomatic factors [4]. Particular
attention has been paid to the question whether genetic
predisposition towards schizophrenia confers genetically
reduced susceptibility to cancer. The protein product of
the tumor suppressor gene p53 is a cell-cycle checkpoint
control protein that assesses DNA damage and acts as a
transcription factor regulating genes, which control cell
growth, DNA repair, and apoptosis. However, little is known
whether patients with schizophrenia possess genetic factors
that also confer tumor resistance, especially to lung cancer
[5, 6], which suggested that the reduced incidence of
cancer observed in schizophrenia patients might be linked
to diﬀerences in apoptosis and proposed p53, a tumor-
suppressor gene, which is considered as a candidate gene for
the susceptibility. The p53 gene is one of the most frequently
mutated genes in all types of cancers including lung cancer
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P53 variable number of tandem repeats- (VNTRs-)
and single-nucleotide polymorphisms- (SNPs-) based ap-
proaches have previously been employed to determination
of possible individual susceptibility and association of these
polymorphic sites within p53 gene with lung cancer [6].
Two polymorphic sites in the sequence of the p53 gene, a
BstUI restriction site at codon 72 in exon 4 and an MspI
site in intron 6, have been proposed as responsible for
the susceptibility to lung cancer [7, 8]. In this study, we
investigated polymorphisms in the two restriction sites of
the p53 gene in Turkish schizophrenia patients, lung cancer
patients, and controls.
2.MaterialandMethods
2.1. Subjects. In our hospital-based case-control study, 100
schizophrenic patients (54 males and 46 females), 100
lung cancer patients (90 males and 10 females), and 100
controls (59 males and 41 females) without schizophrenia
were recruited. The schizophrenia patient group consisted
of 100 Turkish schizophrenia patients diagnosed based on
DSM-IV; mean age was 37.2 ± 10.0 years (mean ± SD).
The lung cancer patient group consisted of 100 Turkish
patients diagnosed with histological proven diagnosis of
lung cancer; the mean age was 60.7 ±10.8 years. The 100
normal controls without schizophrenia and lung cancer
diseases was recruited; the mean age was 50.3 ± 17.4y e a r s
(mean ± SD). The control group consisted of unrelated
healthy volunteers free from present, past, and family history
(ﬁrst-degree relatives) of psychiatric illness and any cancer
histories or substance abuse and the exclusion criteria
for the patients. The group consisted of medical students
and hospital personnel of Firat University Medical School.
Subjects with the above-mentioned concomitant diseases
were excluded from the study after relevant laboratory
tests and consultations with appropriate physicians. Control
group was age adjusted according to patients. After the
complete description of the study to the subjects, all subjects
gave informed written consent approval was obtained from
the local Ethic Committee (Ethic Committee of the Firat
University Medical Faculty).
2.2. DNA Extraction. DNA was prepared from 1 to 5mL
blood samples according to salting-out method [7, 9]. The
DNAsampleswerethenstoredat4◦Cuntilusedasatemplate
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2.3. Genotyping. DNA was prepared from 1 to 5mL blood
samples according to salting-out method [9]. Genotyping
of the two polymorphisms, the exon 4 BstUI (codon 72),
and the intron 6 MspI RFLPs were performed as described
previously [7]. Brieﬂy, polymerase chain reaction (PCR)
ampliﬁcation of two fragments encompassing the p53 BstUI
RFLP and the MspI RFLP was performed in total volume of
50ml containing 250ng of genomic DNA, 1.5mM MgCl2,
100mM dNTP, 15pmol of each primer, and 0.5U Taq poly-
merase (GibcoBRL
￿). PCR involved an initial denaturation
at 94◦C for 5 minutes, followed by 35 cycles of denaturation
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Figure 1: Agaros gel electrophoresis of the p53 BstUI and the
p53 MspI PCR products digested with BstUI and MspI restriction
enzymes. (a) A1 allele does not create BstUI restriction site. The
PCR product has 318bp. Presence of CGCC sequence in A2 allele
creates BstUI restriction site which leads to two fragments 182bp
and 136bp. (b) A1 allele does not create MspI restriction site.
T h eP C Rp r o d u c th a s2 4 0b p .P r e s e n c eo fC C G Gs e q u e n c ei nA 2
allele creates MspI restriction site which leads to two fragments
164bp and 76bp. Lanes 1, 6: 100bp DNA ladder; lanes 2, 7:
1-1 homozygotes; lanes 3, 8: 1-2 heterozygotes; lanes 4, 9: 2-2
homozygotes;lane 5: no DNA in PCR reaction (blank).
at 94◦C for 1 minute, annealing at 58◦Cf o r1m i n u t e ,a n d
extension at 72◦C for 1 minute, with a ﬁnal extension at
72◦C for 12 minutes. The BstUI RFLP sense primer 5 -TTT
CACCCATCTACAgTCCC-3  andtheantisense primer5 -
ACC TAg GCT CAg ggC AAC TgA CCg-3  ampliﬁed a 318-
bp PCR product [10]. The MspI RFLP sense primer 5 -T A T
gAg CCg CCT gAg gTC Tgg-3  and the antisense primer 5 -
TACAggCATgAgCCACTgCgC-3  ampliﬁeda240-bpPCR
product [11]. Ten percent of PCR products were digested
with BstUI (New England BioLabs) at 60◦Cf o r2 hw i t h
MspI (New England BioLabs) at 37◦Cf o r3h .D i g e s t sw e r e
separated on a 3% agarose gel with ethidium bromide. The
electrophoresis was run for 2.5h at 150V. DNA fragments
were stained with ethidium bromide. The ethidium bromide
staining fragments were analyzed on UV source using the
image analysis system Kodak EDAS 120 (Figure 1).
In this study we inspected two polymorphic sites within
the sequence of, the p53 gene: a BstUI restriction fragment
length polymorphism (RFLP) at codon 72 in exon 4 and a
MspI RFLP in intron 6. The BstUI RFLP recognizes a SNP
at codon 72 that either encodes a proline (CCC, allele A1) or
an arginine (CGC, allele A2). MspI recognizes polymorphic
site in intron 6 consisting of either six or eight variable
bases. The BstUI A1 and the MspI A1 allele are both alleles
not presenting the restriction enzyme recognition sites. The
presence of each restriction site was indicated as “A1”; “A2”
was used to indicate absence of the restriction site. Subjects
were scored as “A1–A1”, “A2–A2” (homozygotes), or “A1–
A2” (heterozygote) according to the restriction pattern [12].Genetics Research International 3
Table 1: General characteristics of the control group, lung cancer
patients, and schizophrenia patients.
Characteristic Lung cancer
patients
Schizophrenia
patients Control group
Males n (%) 90 54 59
Females n (%) 10 46 41
Age, mean (SD),
years 60.7 ±10.83 7 .2 ±10.05 0 .3 ±17.4
Smokingstatus nn n
Smokers 88 94 43
Nonsmokers 12 6 57
Alcohol
consumption nn n
Drinking 34 30 12
Nonalcoholic 66 70 88
2.4. Statistical Analyses. Genotype allele and haplotype fre-
quencies of schizophrenia and lung cancer patients with
control groups were compared via the chi-square test and
Fisher’s exact test. Comparisons for sex, genotype, and allele
frequencies for lung cancer patients, schizophrenic patients,
and healthy controls were performed using the chi-square
test. The odds ratio (OR) and its 95% conﬁdence interval
(95% CI) were used to analyze the frequencies of alleles and
genotypes. For all of the tests, the criterion for signiﬁcance
was set at P<. 05. Data are presented as mean ± SD.
Hardy-Weinberg equilibrium was tested for with a goodness
of ﬁt x2 test with 1 degree of freedom to compare the
observed genotype frequencies among the subjects with
the expected genotype frequencies. All calculations were
performed with the SPSS (Statistical Packages of Social
Sciences, SPSS for Windows, Version 11.5, Inc., Chicago, IC,
USA) 15.0 statistical package.
3.Results
The characteristics of the study groups are illustrated in
Table 1. Healthy controls (100 individuals) were about
similar age as lung cancer patients (100 individuals). The
male/female distribution in the healthy group was 59%
versus 41%, in the lung cancer group 90% versus 10%, and
theschizophreniagroup54%versus46%.Smokerswere43%
in the control group and 88% in the lung cancer group
and 94% in the schizophrenia group. Alcohol consumption
were 12% in the control group, 34% in the lung cancer
group, and 30% in the schizophrenia group (Table 1). The
most abundant type of cancer determined histologically was
squamous cell cancer (32%), followed by adenocarcinoma
(16%), large cell carcinoma (9%), and small cell carcinoma
2 9 % .H o w e v e r ,t h e r ew a sa ni m p o r t a n tg r o u pw i t h o u t
histological determination (n = 14, 14%).
The genotype frequencies of BstUI and MspI RFLPs in
theschizophrenia,lungcancer,andcontrolgroupsareshown
in Table 2. For the BstUI polymorphism, there was found
signiﬁcant diﬀerence in the genotype frequencies between
the control and the lung cancer patient groups (genotype
frequency: P<. 001). However, the genotype of the MspI
A1A2showed signiﬁcant diﬀerencesbetweentheschizophre-
nia patient and the control groups (OR 0.81, %95 CI 0.64–
1.1, P<. 001). In addition, the proportion of genotype of
the MspI A1A2 was increased in the schizophrenia (54%)
in comparison to the lung cancer (44%). However, this
deviation did not reach a statistical signiﬁcance (P = .424).
The frequency of A2A2 genotype among lung cancer and
schizophrenia patients was identical (46%) (Table 2).
The allele frequencies of BstUI and MspI RFLPs in the
schizophrenia, lung cancer and control groups are shown
in Table 3. In allele frequencies of BstUI and MspI RFLPs,
signiﬁcant allele frequency diﬀerences were found between
patients and the controls (P<. 001). In our case-control
study, a decreased frequency of the p53 BstUIA1 allele was
foundin lungcancerpatients(P = .09,OR0.23,95%CI0.9–
0.58). However, a signiﬁcant increase of the BstUI A2 and
MspI A1 allele frequency was found in lung cancer patients
(OR 1.22, %95 CI 1.09–1.036; OR 0.87, %95 CI 0.81–0.94)
(Table 3).
The allelic or genotype frequencies based on two p53
polymorphisms were estimated in male and female in
patients and controls. In lung cancer, schizophrenia patients
and Turkish healthy controls stratiﬁed by sex and smok-
ing, and signiﬁcant diﬀerences were observed in genotype
frequencies (P<. 01). In the nonsmoker patients groups
and controls no signiﬁcant diﬀerences were observed in the
genotype frequencies (P = .201).
On comparing control and lung cancer patients, groups
stratiﬁed by smoking, it is possible to observe that only
smokers diﬀer signiﬁcantly in allelic frequencies (P<. 001).
In the non-smoker schizophrenia and lung cancer no sig-
niﬁcant diﬀerences were observed in the allelic frequencies.
The allelic frequency BstUI A1 was higher in male smokers
with lung cancer (1.430) than in the control group (0.416).
The non-smoker group does not present diﬀerencesbetween
controls and lung cancer patients (P = .376). The analyses
in male non-smokers (both control and cancer groups)
showed no diﬀerences in the allelic or genotype frequencies
between bothgroups,suggesting theparticipation ofthisp53
polymorphism in lung cancer associated with smoking. The
frequency of the p53 BstUIA1 allele among schizophrenia
patients (males and females) was increased in the smoker
males and female in comparison to nonsmoker males and
females. Statistical association was demonstrated for allele
frequency in schizophrenia patients (males and females)
when the sample population was stratiﬁed according to sex
and smoking (P<. 01).
Risk of lung cancer from BstUI and MspI genotype with
reference to histological types are shown in Tables 4(a) and
4(b). After grouping of patients according to four main his-
tological types of lung cancer (epidermoid carcinoma, small
cell carcinoma, large cell carcinoma, and adenocarcinoma),
BstUI A1A1 genotype was detected, and adenocarcinoma
(40%) in the lung carcinoma population was increased in
the other histologies. In several epidemiological studies,
there was association between BstUI A1A1genotype and
adenocarcinoma risk. Furthermore, we observed a slight
increaseofBstUIA2/A2genotypesfrequencyinpatientswith4 Genetics Research International
Table 2: BstUI and MspI polymorphisms of the p53 gene genotype frequencies in Turkish schizophrenia and lung cancer patients and
control groups.
Genotype distribution
A1-A1 A2-A2 A1-A2
BstUI n % n % n % X2 P
Schizophrenia (n = 100) 38 38.0 43 43.0 19 19.0 9.620 <.01
Lung cancer (n = 100) 5 5.0 87 87.0 8 8.0 129.740 <.001
Controls (n = 100) 22 22.0 33 33.0 45 45.0 7.940 <.05
MspI
Schizophrenia (n = 100) 0 0.0 46 46.0 54 54.0 .640 .424
Lung cancer (n = 100) 13 13.0 43 43.0 44 44.0 18.620 <.001
Controls (n = 100) 0 0.0 33 33.0 67 67.0 11.660 <.001
aDiﬀerences in genotype and allele frequencies;P<. 01 from Fisher’s exact test.
Table 3: BstUI and MspI polymorphisms of the p53 gene allele
frequencies in Turkish schizophreniapatients, lungcancer patients,
and control groups.
Allele frequency
A1 A2
BstUI
Schizophrenia
(n = 100) 0.48 0.53
32.092 P<. 001
Lung cancer
(n = 100) 0.09 0.91
Controls
(n = 100) 0.45 0.56
MspI
Schizophrenia
(n = 100) 0.27 0.73
27.178 P<. 001
Lung cancer
(n = 100) 0.35 0.65
Controls
(n = 100) 0.34 0.67
aDiﬀerences in genotype and allele frequencies; P<. 01 from Fisher’s exact
test.
epidermoid and small cell carcinoma. The A1A1 genotype
may also play a role in four main histological types of lung
cancer development (Tables 4(a) and 4(b)).
We found a signiﬁcantly higher proportion of p53
MspI heterozygotes (A1A2) in epidermoid and small cell
carcinoma patients (X2: 1.146, P = .979). Only the MspI
heterozygotes (A1A2) that had a small cell carcinoma and
epidermoid showed the signiﬁcant diﬀerence from healthy
controls (Tables 4(a) and 4(b)). OR was calculated to be 3.24
(95% CI 1.07–9.85, P = .979 ). The MspI heterozygotes with
otherhistologiesalso showed thetendencytowardsincreased
OR, but this was not signiﬁcant. Thus, there seems to be no
consistent association between MspI heterozygous genotype
and histological types of lung cancers.
The diﬀerences of allele frequencies were estimated
according to histological types of lung cancer patients. The
proportion of Pro BstUI and MspI (A1) allele was found in
epidermoid carcinoma. Furthermore, we observed a slight
decrease of BstUI and MsPI allele frequency in patients with
adenocarcinoma and large cell carcinoma (Table 5).
The haplotype frequencies based on two p53 poly-
morphisms were estimated in patients (Table 6). When
the haplotypes had been taken into account, although
the distribution of haplotypes in lung cancer patients
was similar to controls, we did ﬁnd found an interesting
phenomenon. The haplotype carrying the BstUI A2 allele
and MspI A1 allele was not found in healthy controls and
schizophrenia patients in contrast to the presence of this
haplotype in lung cancer patients (12%). In addition, the
estimated frequency of the BstUI A1- MspI A2 haplotype
of schizophrenia patients (39%) was sixfold higher than
that of lung cancer patients (6%). The BstUI A2-MspI A2
haplotypewasobservedinlungcancerpatients(61%),which
was detected in schizophrenia patients (82.2%). Thus, it
could be suggested that the MspI A2 allele, by itself or
perhaps more important in the form of the BstUI A1-
MspI A2 haplotype, is a marker of susceptibility of lung
cancer.
Table 7 presents an estimation of the haplotype frequen-
cies in male and females in patients and the control groups.
Sex diﬀerences were not found in the distribution of BstUI-
MspI haplotype in common population. No signiﬁcant
(P = .844) diﬀerences were found in patients from the
control group. The haplotype combination BstUI A2-MspI
A1 among lung cancer patients (males and females) was
increased in the males (12%) in comparison to females
(10%), which was not detected in schizophrenia patients
and control groups. However, this deviation did not reach
statistical signiﬁcance (P = .098) (Table 7).
4.Discussion
Lung cancer incidence is higher among women than men.
Furthermore, replication would support the hypothesis by
Henschke et al. that women may be more susceptible to
develop lung cancer than men but are less likely to die
from the disease [13]. Studies are also needed to determine
whether the survival diﬀerence between male and female
never smokers is large enough to account for the lower lung.
Lung cancer is the most preventableof all of the major forms
ofcancerbecause 85%to 90%ofdeathsfromlung cancerare
a result of active cigarette smoking. Environmental tobaccoGenetics Research International 5
Table 4
(a) Risk of lung cancer from BstUI genotype with reference to histological types.
Histologicaltypes
p53-BstUI type
A1/A1 A1/A2 A2/A2 Total
n % n % n % n %
Large cell carcinoma 1 20.0 2 28.6 6 8.1 9 10.5
Small cell carcinoma. 1 20.0 2 28.6 26 35.1 29 33.7
Epidermoid carcinoma 1 20.0 3 42.9 28 37.8 32 37.2
Adenocarcinoma 2 40.0 0 0.0 14 18.9 16 18.6
Total 5 100.0 7 100.0 74 100.0 86 100.0
X2: 6.400, df:6, P = .380.
(b) Risk of lung cancer from MspI genotype with reference to histological types.
Histologicaltypes
p53-MspI type
A1/A1 A1/A2 A2/A2 Total
n % n % n % n %
Large cell carcinoma 1 12.5 4 10.8 4 9.8 9 10.5
Small cell carcinoma 2 25.0 12 32.4 15 36.6 29 33.7
Epidermoid carcinoma 4 50.0 13 35.1 15 36.6 32 37.2
Adenocarcinoma 1 12.5 8 21.6 7 17.1 16 18.6
Total 8 100.0 37 100.0 41 100.0 86 100.0
X2: 1.146, df:6, P = .979.
Table 5: The diﬀerences of allele frequencies estimated according
to histologicaltypes of lung cancer patients.
Allele BstUI A1 A2
Group Histological types
Lung cancer
Large cell carcinoma 34.3 22.4
Small cell carcinoma 34.3 49.4
Epidermoid carcinoma 41.5 59.2
Adenocarcinoma 40.0 18.9
Allele MspI
Lung cancer
Large cell carcinoma 17.9 15.2
Small cell carcinoma 41.2 52.8
Epidermoid carcinoma 67.5 54.1
Adenocarcinoma 23.3 27.9
s m o k ei so f t e ns t a t e dt ob et h em a j o rc a u s eo fl u n gc a n c e r
[14].
The majority of the causative factors of lung cancer are
well established. Tobacco smoking is the most important
factor. The incidence of lung cancer is related to the preva-
lence of smoking in a population. In a study from Denmark,
it was observed that the incidence of lung cancer declined
slightly in association with a decline in the prevalence of
smoking in men [15]. Tobacco smoking continues to be a
major problem in Turkey, where the number of smokers
increases daily. In our study, we observed that approximately
90% of the patients were smokers or exsmokers. Smoking
among women in Turkey is not as common as among men,
and this was reﬂected in the predominance of male patients
(90.4%) in this study. The dominance of males among lung
cancer patients has also been observed in other studies from
Turkey [16, 17].
This study shows that the frequency of epidermoid car-
cinoma was clearly higher than that of other subtypes. Epi-
dermoid carcinoma is the most common subtype in Asian
countries such as Korea and China [18, 19]. In contrast,
adenocarcinoma is currently the most frequent histological
type in the United States and Japan [20, 21]. Although
adenocarcinomaisincreasinginprevalenceamongEuropean
women, it is not yet the most predominant cancer in Europe
[22]. The reasons for this shift are not clear although the rise
in the incidence of lung cancer in women plays some part.
Otherpossible factors includechanges in smokinghabitsand
cigarettes or other environmental exposure. Smokers of low-
yield ﬁlter-tipped cigarettes have to take more frequent and
larger puﬀs to satisfy their need for nicotine. This allows
the cigarette smoke to reach the distant branches of the
bronchioalveolar tree, where adenocarcinoma usually occurs
[23].In additiontothesefactors, some authorsclaimthatthe
increase intheincidenceofadenocarcinomamightberelated
to a better histological diagnosis of tumors which were
previously called ‘unspeciﬁed epithelial carcinomas [24]. In
our study, it is of interest to note that 16% of patients did
not have a speciﬁc histological diagnosis, and 9% of patients
were diagnosed as unspeciﬁed large cell carcinoma. The
incidence of adenocarcinoma might, therefore, have been
higher if the deﬁnitive histological subtypes of these patients
had been diagnosed. Large cell carcinoma was observed at
a low frequency in our study (9%) when compared with
other studies from diﬀerent countries (about 10% of lung
cancers) [15, 24]. We cannot exactly explain the reason for6 Genetics Research International
Table 6: Estimated haplotype frequencies of the BstUI and MspI polymorphisms of the p53 gene.
Estimated haplotype frequency
A1-A1 A2-A2 A1-A2 A2-A1
Haplotype BstUI-MspI n % n % n % n % X2 P
Schizophrenia 0 0.0 61 61.0 39 39.0 0 0.0 4.840 <.05
Lung cancer 0 0.0 82 82.0 6 6.0 12 12.0 107.120 <.001
Control 0 0.0 79 79.0 21 21.0 0 0.0 33.960 <.001
aSigniﬁcant pairwise association and linkage disequilibriumbetween the two polymorphisms; P<. 001.
Table 7: Estimated pairwise haplotype frequencies between the BstUI and MspI polymorphisms in lung cancer patients and controls.
Estimated haplotype frequency
A1-A1 A2-A2 A1-A2 A2-A1 Total
Haplotype n % n %% n % nX 2 P
Schizophrenia Male 0 0.0 33 61.1 21 38.9 0 0.0 54 .339 .844
Female 0 0.0 28 60.9 18 39.1 0 0.0 46
Lung cancer Male 0 0.0 74 82.2 5 5.6 11 12.2 90 .001 .98
Female 0 0.0 8 80.0 1 10.0 1 10.0 10
Control Male 0 0.0 48 81.4 11 18.6 0 0.0 59 .481 .488
Female 0 0.0 31 75.6 10 24.4 0 0.0 41
aCases versus control.
this, but we think that some large cell carcinomas might
have been established as unspeciﬁed large cell carcinoma due
to the diﬃculty of making a diagnosis of large cell cancer
in small, poorly preserved bronchoscopic biopsy specimens.
Small cell carcinoma constitutes 20%–25% of lung cancer
patients [15, 25]. We observed a similar frequency of small
cell carcinoma (29%). This suggests that large cell carcinoma
is diagnosed at more advanced stages in Turkey than in
developed countries. The largest number of data so far
collected in Turkey shows that the vast majority of patients
with lung cancer are male, epidermoid cell is the most
commonhistologicaltype,approximately 90%ofpatientsare
currentorexsmokers,andonlyasmallproportionofpatients
are diagnosed at an early stage. The diﬃculty in making an
early diagnosis and in starting early treatment of lung cancer
indicates the importance of combating tobacco. Education
regarding the prevention of smoking initiation in youth and
more eﬀective eﬀorts toward smoking cessation must be the
main targets of the ﬁght against lung cancer.
Cancer risk in schizophrenia patients has been discussed
over decades. Several studies have reported reduced cancer
incidence in schizophrenia patients in epidemiological per-
spectives [26]. But the mechanism underlying this diﬀerent
occurrence between cancer and schizophrenia has not been
elucidated.Recently,geneticbackgrounds,whichregulatethe
various biological processes, are suggested as possible causes
ofthisphenomenon. However, to date,few studieshavebeen
performed concerning the relationship between schizophre-
nia pathogenesis and cancer development. Previous studies
have found that the incidence of cancer in schizophrenic
patients is reduced. Especially, the incidence of lung cancer
for schizophrenic patients is lower than for the general
population, which is unexpected because schizophrenic
patients smoke more than the general population. Secondly,
schizophrenia is generally considered to be a neurode-
velopmental disorder [27]. Candidate neurodevelopmental
molecules related to cell proliferation, axonal outgrowth,
synapticregression, myelination,andcellmigrationmightbe
implicatedin schizophrenia [28].Komarovaetal. foundthat
p53 was strongly expressed in speciﬁc mouse brain regions,
suggesting that the p53 gene is involved in the development
of the nervous system [27, 29]. Finally, there is evidence
that increased expression of p53 in an early stage of brain
development results in neuronal damage, and the increased
neuronal apoptosis may partially explain the high incidence
of neuromotoranomalies found in schizophrenia. The above
ﬁndings point to the p53 gene as possibly being involved in
the pathogenesis of schizophrenia.
When the distribution of genotype and allele had been
taken into account, in our previous case-control study, a
decreased frequency of the p53 MspI A1/A2 genotype was
found in bladder cancer. More recently, both Wang et al.
[29]a n dK a w a j i r ie ta l .[ 7] in earlier studies reported a
relationship between the p53 BstUI A1/A1 genotype and
lung cancer in Asiatic populations of Taiwan and Japan. In
studiesfromSweden ofnasopharyngeal cancerand Germany
of breast cancer, signiﬁcant associations of the p53 BstUI
A1/A1 and the p53 MspI A1/A2 genotypes were observed
[8, 10, 30, 31]. The consistent association between the p53
SNPs(p53BstUIandp53MspI)andvariousformsofhuman
malignancies may serve as arguments in favor of these
polymorphic sites as genetic determinants of susceptibility.
In our studies, signiﬁcant diﬀerence was found in
genotypeand allele frequenciesoftheMspI andBstUIRFLPs
between lung cancer patients, schizophrenia patients, and
healthy normal Turkish control (data not shown). There wasGenetics Research International 7
signiﬁcantly higher BstUI A2A2 genotype in lung cancer
patients (OR 0.73; OR 0.28). The frequencies of BstUI A1A1
genotype was found signiﬁcantly lower (5%). In addition,
control (22%) and patients with schizophrenia (38%) were
observed higher of frequencies of BstUI A2A2 genotype (OR
0.19; OR 0.81). The Pro-Pro (BstUI A1A1, encoded proline)
genotype was estimated to be associated with increased risk
forlungcancer.TheincreasedfrequencyoftheBstUlAl(pro)
allele was more pronounced in highly diﬀerentiated lung
cancer. These results suggest that thep53 BstUl Al(pro)allele
may inﬂuence increase lung cancer cancer.
In our case-control study, a increased frequency of
the p53 MspI A1/A2 genotype was found between the
schizophrenia and the lung cancer patient groups. However,
this deviation did not reach a statistical signiﬁcance (P =
.424). However, the signiﬁcant diﬀerences in the genotype
and allele frequencies of the MspI polymorphism in the
p53 gene between the schizophrenia and the lung cancer
patient groups suggest that the p53 polymorphisms could be
a marker for lower susceptibility to lung cancer genetically in
schizophrenia patients. On the other hand, there were some
additional interesting results revealed. For the BstUI and
MspI polymorphism, there was signiﬁcant diﬀerence in the
genotype and allele frequencies between the schizophrenia
patient and the lung cancer patient groups (X2 = 32.092P<
.001; X2 = 27.178, P<. 001, Table 2 versus Table 3). In
addition, a correlation between the presence of the MspI
A2 allele and increased odds ratio for lung cancer (OR
2.98, 95% CI 1.46–6.09) was observed. The proportion of
BstUI A1 allele was decreased in lung cancer patient in
comparison to the healthy control and the schizophrenia.
However, the incidence of BstUI A2 allele was increased in
lung cancer patient. This results suggested that A1 allele
could be a protective eﬀect against lung cancer. Although
incidence of A1 allele was observed slightly lower in lung
cancer patient, the ratio of this allele was signiﬁcantly
increased. The above ﬁndings point to the A1 allele as
possibly being involved in the pathogenesis ofschizophrenia.
Finally, this ﬁnding may explanation reason of the incidence
of cancer in schizophrenic patients is reduced. This ﬁnding
is important. Our results imply that genetic predisposition
towards schizophrenia may oﬀer reduced vulnerability to
lung cancer.
The polymorphism of p53 gene at codon 72 consisting
of either arginine- (Arg-) or proline- (Pro-) encoded allele is
suggested to be associated with the susceptibility of tobacco-
related lung cancer [32]. Yet, the BstUI A1 (Pro) allele
carriers among the smoker lung cancer patients showed
higher rate than control group. Thus, the present data
showed that the p53 polymorphism could be associated with
the susceptibility of tobacco-related lung cancer.
When the diﬀerences of genotype and allele frequencies
estimated according to histological types of lung cancer had
been taken into account, Fan et al. and Weston et al. [31, 32]
reported that he Pro/Pro homozygous genotype occurred
more frequently in adenocarcinomas. The prevalence of the
Pro/Pro genotype in adenocarcinoma was higher than that
of other genotypes and increased with increasing pack years.
The prevalence of the Pro/Pro genotype in adenocarcinoma
cases was statistically diﬀerent from that of the controls. A
Japanese study reported that the prevalence of the Pro/Pro
variant in patients with adenocarcinoma was 1.2-fold higher,
which was not statistically diﬀerent from controls. [8]
Weston et al. [32] reported a prevalence of 26% for their
pooled control group and 21% in all types of lung cancer
combined.Jin etal.[33]reportedthatthesusceptiblePro/Pro
genotype was associated with a 1.6-fold higher risk of all
typesoflungcancercombinedinAfrican Americansand1.9-
fold higherrisk in Mexican Americans, with neitherreaching
statistical signiﬁcance. In our study, the frequency of the
Pro/Pro genotype in adenocarcinoma was much lower than
that of the Arg/Arg genotype.
We found a signiﬁcantly higher proportion of p53 MspI
heterozygotes (A1 A2) in epidermoid and adenocarcinoma
patients (X2: 1.146, P = .979). However, among lung
cancer patients who had p53 MspI heterozygous genotype,
epidermoid and small cell carcinoma patients showed a
signiﬁcant diﬀerence (P = .979) when comparisons were
based on histological types of lung cancer. Thus, there seems
to be no consistent association between MspI heterozygous
genotype and histological types of lung cancer. The fact
that MspI polymorphism is located in noncoding region
of the p53 gene (intron 6) oﬀers support to the idea that
this polymorphic site is not functionally involved in lung
carcinogenesis but rather in linkage disequilibrium with
some speciﬁc susceptibility site on the p53 gene. In addition
to the BstUI A1A1 genotype of lung cancer patients (40%),
adenocarcinoma and other histological types of lung cancer
were detected. Several epidemiological studies have found
an association between risk of adenocarcinoma and presence
of BstUI A1A1 genotype. Interestingly, proportion of BstUI
A2/A2 genotype was signiﬁcantly higher in epidermoid car-
cinoma. The A1A1 genotype may inﬂuence the development
of histological subtypes of lung cancer (Tables 4(a) and
4(b)). The Pro-Pro (BstUI A1A1, encoded proline) genotype
was estimated to be associated with increased risk for lung
cancer [6] because the apoptotic eﬀect is lower than Arg/Arg
genotype of this genotype. Epidemiological studies of genes
that oppose and inhibit cell-cycle progression may shed
additional light on the relationship between incidence of
cancer and that of schizophrenia, the present authors believe
that the literature is suﬃciently consistent to suggest that
the mechanism underlying the apparent tumour resistance
in schizophrenia may be of aetiological signiﬁcance to
schizophrenia itself. One possible mechanism which plays
a central role in both tumorigenesis and neurodevelop-
ment is apoptosis. Apoptosis is the physiological process
of genetically programmed cell death. Apoptosis is closely
related to the processes promoting the life cycle of the
cell. All cells contain clock-like machinery which controls
orderly progression of the cell through the stages of its
life cycle. These transitions start with mitosis (M) and
proceed to a period of growth or diﬀerentiation (G1),
hence to DNA synthesis (S) before a second period of
growth (G2) leads again to mitosis, completing the life cycle.
Cells that do not go on to mitosis may enter a quiescent
growth-stage end point (G0). Growth factors and activated
oncogenes are positive regulators of cell-cycle progression.8 Genetics Research International
Some genes, called tumour-suppressor genes, oppose cell-
cycle progression and inhibit uncontrolled cell proliferation
by deactivating proteins encoded by oncogenes. At all stages
of the cell cycle, DNA integrity is checked. If damage has
occurred and DNA repair is not possible, the cell normally
undergoes apoptosis and is eliminated. Thus, apoptosis is a
key mechanism for removing cells with DNA damage and
which are therefore potentially precancerous. Cancer results
from uncontrolled cell proliferation, usually due to gene
mutations causing abnormalities in the protein regulators
of the cell cycle. Cancerous cells have a decreased ability to
undergo apoptosis [4].
The process of bronchial carcinogenesis is characterized
by accumulated genetic abnormalities which ultimately lead
to malignant transformation ofbronchial epithelial cells, fol-
lowed by invasion and metastasis. One of the most common
and consistent of these genetic lesions is inactivation of the
p53tumorsuppressorgenebymutationordeletion[34].The
frequencyofp53alterations in lungcancerishighest in those
subtypes of bronchial carcinomas that are most consistently
associated with smoking, especially small cell carcinoma and
epidermoidcarcinomas. An understanding of the role of p53
in human lung cancer may lead to more rational targeted
approaches for treating this disease.
Association of p53 codon 72 polymorphism with lung
cancer risk has been studied by several groups although
with inconsistent results. The pro allele was found to be
in excess in patients with adenocarcinoma in an American
study. A study carried out in Japan showed that a signiﬁcant
association of the Pro allele with the small cell carcinoma
group, but not in adenocarcinoma [35]. In our study, Pro
BstUI and MspI (A1) allele of p53 increased the risk in
epidermoid carcinoma and proportion of this allele was
observed decreased in large cell carcinoma. However, the
ratio of BstUI and MspI A2 allele was observed slightly
decreased adenocarcinoma and large cell carcinoma. The
hypothesiswasthatindividualswhopossessahighernumber
of variant p53 pro alleles would be at higher risk for
lung cancer. Yet, our results only agreed with other case-
control studies. These above ﬁndings imply that the p53
codon 72 polymorphism may play a putative role in the
etiopathogenesis of epidermoid carcinoma in Turkey.
The estimation of p53 haplotypes revealed an interesting
phenomenon. Consequently, the most common (wild-type)
haplotype combination is A2-A2, that is, the p53 BstUI
A2 allele (or Arg allele) linked to presence of the MspI
restriction site. The next haplotype in frequency (A1-A2)
diﬀers from the “wild type” in only one mutation, and
the third haplotype in frequency (A1-A1) contains two
mutational events with respect to the wild type [27]. The
haplotypecarrying BstUIA2allele and MspI A1allele, which
was found in only 1.2% among the Swedish controls and in
none of Swedish lung cancer patients [36], had a frequency
of 5.4% in cancer patients and null among healthy controls
in our study. The haplotype carrying the BstUI A2 allele and
MspI A1 allele was not found in healthy controls in contrast
to the presence of this haplotype in Slovak lung cancer
patients (5.4%) [6]. Our results only agreed with those of
Birgander et al. when lung cancer patients were compared
with healthy controls concerning to BstUI polymorphism
[36]. In our study, the haplotype carrying the BstUI A2 allele
and MspI A1 allele was not found in healthy controls and
schizophrenia in contrast to the presence of this haplotype
in Turkish lung cancer patients (12%). It is interesting in
this context that there exist the ethnic diﬀerences in cancer
susceptibility modulated by p53 polymorphic sites. This
suggestion is supported by other studies of the codon 72
polymorphism (BstUI), which have revealed striking ethnic
diﬀe r e n c e s .T h eh a p l o t y p ec a r r y i n gt h eT h eB s t U IA 1 -
MspI A2 haplotype was not found in healthy controls and
schizophrenia. In addition, the estimated frequency of the
BstUI A2-MspI A2 haplotype of lung cancer patients was
higher than that of schizophrenia patients. Thus, it could be
suggested that the MspI A2 allele, by itself or perhaps more
important in the form of the BstUI A1-MspI A2 haplotype,
is a marker ofsusceptibility of lung cancer.
However, the signiﬁcant diﬀerences in the genotype and
allele frequencies of the MspI polymorphism in the p53
gene between the schizophrenia and the lung cancer patient
groups suggest that the p53 polymorphisms could be a
marker for lower susceptibility to lung cancer genetically
in schizophrenia patients. Furthermore, our results imply
that genetic predisposition towards schizophrenia may oﬀer
reduced vulnerability to lung cancer. However, further stud-
ies involving larger, better age-matched sample populations
would be necessary for more concrete results in order
to conﬁrm the our results. Moreover, it is necessary to
investigate more SNPs in the p53 gene or other genes related
to apoptosis for better understanding of the relationship
between schizophrenia and cancer.
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